Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection.
- Author:
Jungmin JO
1
;
Dok Hyun YOON
;
Sang Wook LEE
;
Chan Sik PARK
;
Jooryung HUH
;
Kyoungmin LEE
;
Eun Hee KANG
;
Shin KIM
;
Cheolwon SUH
Author Information
- Publication Type:Original Article
- Keywords: Diffuse large B-cell lymphoma; Limited Stage; Resection; Abbreviated chemotherapy
- MeSH: B-Lymphocytes; Disease-Free Survival; Drug Therapy*; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Lymphoma, B-Cell*; Lymphoma, Non-Hodgkin; Radiotherapy; Recurrence; Retrospective Studies; Survival Rate
- From:Blood Research 2014;49(2):115-119
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Abbreviated chemotherapy followed by radiotherapy or full cycles of chemotherapy is recommended as a standard treatment for limited-stage (LS) diffuse large B-cell lymphoma (DLBCL). After complete resection of tumors, however, Burkitt and childhood B-cell Non-Hodgkin lymphoma show favorable outcomes, even after abbreviated chemotherapy of only 2 or 3 cycles. We investigated the effectiveness of abbreviated chemotherapy in patients with LS DLBCL after complete tumor resection. METHODS: We retrospectively reviewed 18 patients with LS DLBCL who underwent complete tumor resection followed by either 3 or 4 cycles of chemotherapy between March 2002 and May 2010. RESULTS: With a median follow-up period of 57.9 months (range, 31.8-130.2 months), no patients experienced disease relapse or progression; however, 1 patient experienced secondary acute myeloid leukemia during follow-up. The 5-year progression-free survival rate and overall survival rate were 93.3% and 94.1%, respectively. CONCLUSION: These results warrant further investigation into abbreviated chemotherapy as an alternative treatment for patients who have undergone complete resection of LS DLBCL.
